KODIAK SCIENCES INC.
About KODIAK SCIENCES INC.
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. It focuses on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC® Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery efforts. The company is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients into its proprietary biopolymer backbone.
- 🔗 Kodiak Sciences - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares | Kodiak Sciences Inc.
- 🔗 Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
- 🔗 Kodiak Sciences’ Upsized Equity Raise Could Be A Game Changer For Kodiak Sciences (KOD)
- 🔗 Kodiak Sciences Announces Proposed Public Offering of Common Stock | Kodiak Sciences Inc.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Completed $184M public offering of common stock in December 2025 including full underwriter option exercise.
- Total prior funding of $35.8M across three rounds with latest being conventional debt in 2018.
- Developing retinal medicines via ABC Platform for leading causes of blindness with no current revenue.
- Public company on Nasdaq: KOD focused on molecular engineering for protein and chemistry-based therapies.
Ask StreetZero about KODIAK SCIENCES INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account